Literature DB >> 21360074

Molecular and epidemiological characteristics of inflammatory breast cancer in Algerian patients.

Nabila Chaher1, Hugo Arias-Pulido, Nadija Terki, Clifford Qualls, Kamel Bouzid, Claire Verschraegen, Anne Marie Wallace, Melanie Royce.   

Abstract

Inflammatory breast cancer (IBC) shows a high incidence in Tunisia and Egypt but epidemiological and molecular characteristics have not been described in Algeria. We compared 117 IBC and 59 non-IBC locally advanced breast cancers (LABC), for estrogen and progesterone receptors, HER2, and EGFR protein expression by immunohistochemistry, and HER2 gene amplification by chromogenic in situ hybridization. Demographic, clinico-pathological, and molecular variables were compared with chi-square and Fisher's exact tests to test for significance (P < 0.05, two-tailed). Overall survival (OS) and disease-free survival (DFS) were plotted using Kaplan-Meier curves and compared using the log-rank test. Tumor emboli were detected in 77% of IBC. Palpable masses were found in all LABC but only in 32% of IBC (P < 0.001). Recurrences were higher in LABC than in IBC (48 vs. 35%; P = 0.14) but OS was worse in IBC (68 vs. 71%; P = 0.06). There were no significant differences between IBC and LABC by demographics or by clinico-pathological parameters. The majority of IBC and LABC tumors were luminal A (62 and 64%), followed by basal (~18%, each), triple negative (~18%, each), and HER2+ (~10%, each) subtypes. In multivariate analyses, grade was associated with worse OS (P = 0.04), and DFS (P < 0.001) in IBC; chemo- and radio-therapy were associated with improved OS and DFS, respectively (P < 0.05 for each) in LABC. In conclusion, IBC in Algeria shows similar characteristics to IBC described for Egypt and Tunisia with subtle molecular differences. Current therapeutic treatments were not very effective in this population and new approaches are much needed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21360074      PMCID: PMC3564504          DOI: 10.1007/s10549-011-1422-5

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  34 in total

1.  Prognosis of dermal lymphatic invasion with or without clinical signs of inflammatory breast cancer.

Authors:  Guenther Gruber; Michele Ciriolo; Hans Joerg Altermatt; Stefan Aebi; Gilles Berclaz; Richard H Greiner
Journal:  Int J Cancer       Date:  2004-03       Impact factor: 7.396

Review 2.  Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health.

Authors: 
Journal:  Obes Res       Date:  1998-09

3.  Case control study of prognostic markers and disease outcome in inflammatory carcinoma breast: a unique clinical experience.

Authors:  S A Aziz; S Pervez; S Khan; N Kayani; S I Azam; M H Rahbar
Journal:  Breast J       Date:  2001 Nov-Dec       Impact factor: 2.431

4.  Inflammatory breast cancer survival: the role of obesity and menopausal status at diagnosis.

Authors:  S Chang; J R Alderfer; L Asmar; A U Buzdar
Journal:  Breast Cancer Res Treat       Date:  2000-11       Impact factor: 4.872

5.  International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment.

Authors:  S Dawood; S D Merajver; P Viens; P B Vermeulen; S M Swain; T A Buchholz; L Y Dirix; P H Levine; A Lucci; S Krishnamurthy; F M Robertson; W A Woodward; W T Yang; N T Ueno; M Cristofanilli
Journal:  Ann Oncol       Date:  2010-07-05       Impact factor: 32.976

6.  Epidemiologic features of rapidly progressing breast cancer in Tunisia.

Authors:  N Mourali; L R Muenz; F Tabbane; S Belhassen; J Bahi; P H Levine
Journal:  Cancer       Date:  1980-12-15       Impact factor: 6.860

7.  Inflammatory breast cancer and body mass index.

Authors:  S Chang; A U Buzdar; S D Hursting
Journal:  J Clin Oncol       Date:  1998-12       Impact factor: 44.544

8.  Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'.

Authors:  Emmanuelle Charafe-Jauffret; Carole Tarpin; Valérie-Jeanne Bardou; François Bertucci; Christophe Ginestier; Anne-Chantal Braud; Brigitte Puig; Jeannine Geneix; Jacques Hassoun; Daniel Birnbaum; Jocelyne Jacquemier; Patrice Viens
Journal:  J Pathol       Date:  2004-03       Impact factor: 7.996

9.  Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers.

Authors:  Christophe Ginestier; Emmanuelle Charafe-Jauffret; François Bertucci; François Eisinger; Jeannine Geneix; Didier Bechlian; Nathalie Conte; José Adélaïde; Yves Toiron; Catherine Nguyen; Patrice Viens; Marie-Joelle Mozziconacci; Rémi Houlgatte; Daniel Birnbaum; Jocelyne Jacquemier
Journal:  Am J Pathol       Date:  2002-10       Impact factor: 4.307

10.  Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancer.

Authors:  G G Van den Eynden; I Van der Auwera; S Van Laere; C G Colpaert; P van Dam; S Merajver; C G Kleer; A L Harris; E A Van Marck; L Y Dirix; P B Vermeulen
Journal:  Breast Cancer Res Treat       Date:  2004-05       Impact factor: 4.872

View more
  15 in total

1.  The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.

Authors:  H Arias-Pulido; A Cimino-Mathews; N Chaher; C Qualls; N Joste; C Colpaert; J D Marotti; M Foisey; E R Prossnitz; L A Emens; S Fiering
Journal:  Breast Cancer Res Treat       Date:  2018-06-01       Impact factor: 4.872

2.  Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.

Authors:  Angie M Torres-Adorno; Jangsoon Lee; Takahiro Kogawa; Peter Ordentlich; Debu Tripathy; Bora Lim; Naoto T Ueno
Journal:  Clin Cancer Res       Date:  2017-05-02       Impact factor: 12.531

3.  Clinico-pathologic and mammographic characteristics of inflammatory and non-inflammatory breast cancer at six centers in North Africa.

Authors:  Catherine Schairer; Ahmed Hablas; Ibrahim AbdelBar Seif Eldein; Rabab Gaafar; Henda Rais; Amel Mezlini; Farhat Ben Ayed; Wided Ben Ayoub; Abdellatif Benider; Ali Tahri; Mouna Khouchani; Dalia Aboulazm; Mehdi Karkouri; Saad Eissa; Ruth M Pfeiffer; Shahinaz M Gadalla; Sandra M Swain; Sofia D Merajver; Linda Morris Brown; Amr S Soliman
Journal:  Breast Cancer Res Treat       Date:  2019-04-22       Impact factor: 4.872

4.  Differential effects of CD20+ B cells and PD-L1+ immune cells on pathologic complete response and outcome: comparison between inflammatory breast cancer and locally advanced breast cancer patients.

Authors:  Hugo Arias-Pulido; Ashley Marie Cimino-Mathews; Nabila Chaher; Clifford Ray Qualls; Nancy Joste; Cecile Colpaert; Jonathan Douglas Marotti; Mary Dickinson Chamberlin; Maxwell Gabriel Foisey; Eric Robert Prossnitz; Leisha Ann Emens; Steven Fiering
Journal:  Breast Cancer Res Treat       Date:  2021-09-20       Impact factor: 4.872

5.  Tumor stromal vascular endothelial growth factor A is predictive of poor outcome in inflammatory breast cancer.

Authors:  Hugo Arias-Pulido; Nabila Chaher; Yun Gong; Clifford Qualls; Jake Vargas; Melanie Royce
Journal:  BMC Cancer       Date:  2012-07-19       Impact factor: 4.430

6.  Clinical Implications of iNOS Levels in Triple-Negative Breast Cancer Responding to Neoadjuvant Chemotherapy.

Authors:  Zining Jin; Wenqian Wang; Nan Jiang; Lei Zhang; Yiming Li; Xiaoyin Xu; Shouliang Cai; Liang Wei; Xuhong Liu; Guanglei Chen; Yizhen Zhou; Cheng Liu; Zhan Li; Feng Jin; Bo Chen
Journal:  PLoS One       Date:  2015-07-21       Impact factor: 3.240

7.  Prevalence of papillomaviruses, polyomaviruses, and herpesviruses in triple-negative and inflammatory breast tumors from algeria compared with other types of breast cancer tumors.

Authors:  Marilys Corbex; Sabiha Bouzbid; Alexandra Traverse-Glehen; Hayette Aouras; Sandrine McKay-Chopin; Christine Carreira; Abdelaziz Lankar; Massimo Tommasino; Tarik Gheit
Journal:  PLoS One       Date:  2014-12-05       Impact factor: 3.240

8.  Matriptase regulates c-Met mediated proliferation and invasion in inflammatory breast cancer.

Authors:  Gina L Zoratti; Lauren M Tanabe; Thomas E Hyland; Michael J Duhaime; Éloïc Colombo; Richard Leduc; Eric Marsault; Michael D Johnson; Chen-Yong Lin; Julie Boerner; Julie E Lang; Karin List
Journal:  Oncotarget       Date:  2016-09-06

9.  Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers.

Authors:  Hiroko Masuda; Keith A Baggerly; Ying Wang; Takayuki Iwamoto; Takae Brewer; Lajos Pusztai; Kazuharu Kai; Takahiro Kogawa; Pascal Finetti; Daniel Birnbaum; Luc Dirix; Wendy A Woodward; James M Reuben; Savitri Krishnamurthy; W Symmans; Steven J Van Laere; François Bertucci; Gabriel N Hortobagyi; Naoto T Ueno
Journal:  Breast Cancer Res       Date:  2013-11-25       Impact factor: 6.466

Review 10.  Receptor-defined subtypes of breast cancer in indigenous populations in Africa: a systematic review and meta-analysis.

Authors:  Amanda Eng; Valerie McCormack; Isabel dos-Santos-Silva
Journal:  PLoS Med       Date:  2014-09-09       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.